[55] García-Gutiérrez V,

Hernández-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: Efficacy and safety. Frontiers in Oncology. 2019;**9**:603. DOI: 10.3389/ fonc.2019.00603

[56] Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. American Journal of Hematology. 2016;**91**(2):252-265. DOI: 10.1002/ ajh.24275

[57] Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;**7**(2):129-141. DOI: 10.1016/j. ccr.2005.01.007

[58] O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;**16**(5):401-412. DOI: 10.1016/j.ccr.2009.09.028

[59] Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: An update of concepts and management

*Chronic Myeloid Leukemia DOI: http://dx.doi.org/10.5772/intechopen.90604*

recommendations of European LeukemiaNet. Journal of Clinical Oncology. 2009;**27**(35):6041-6051. DOI: 10.1200/JCO.2009.25.0779

[60] Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. The New England Journal of Medicine. 2003;**349**(15):1423-1432. DOI: 10.1056/ NEJMoa030513

[61] Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;**108**(6):1809-1820. DOI: 10.1182/ blood-2006-02-005686

[62] Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;**112**(8):3500-3507. DOI: 10.1182/ blood-2008-02-141689

[63] Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;**352**(9134):1087-1092. DOI: 10.1016/s0140-6736(98)03030-x

[64] Bittencourt H, Funke V, Fogliatto L, Magalhães S, Setubal D, Paz A, et al. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplantation. 2008;**42**(9):597-600. DOI: 10.1038/ bmt.2008.218

[65] Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;**91**(4):513-521

[66] van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation. 1997;**20**(7):553-560. DOI: 10.1038/ sj.bmt.1700933

[67] Devergie A, Apperley JF, Labopin M, Madrigal A, Jacobsen N, Carreras E, et al. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation. 1997;**20**(1):11- 19. DOI: 10.1038/sj.bmt.1700844

[68] Innes AJ, Milojkovic D, Apperley JF. Allogeneic transplantation for CML in the TKI era: Striking the right balance. Nature Reviews. Clinical Oncology. 2016;**13**(2):79-91. DOI: 10.1038/nrclinonc.2015.193

[69] Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;**112**(12):4371-4383. DOI: 10.1182/ blood-2008-03-077974
